Healthcare Services

A Significant Growth Driver for the Choroidal Neovascularization Market Is the Increasing Prevalence Of Age-related Macular Degeneration Driving Market Growth

March 31, 2026April 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Will The Market Size Of The Choroidal Neovascularization Market Evolve From 2026 To 2030?

The choroidal neovascularization market has seen substantial growth in recent years. It is anticipated to increase from $4.18 billion in 2025 to $4.5 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.7%. This historical expansion can be linked to factors such as the increasing prevalence of age-related macular degeneration, a rise in diabetic eye disease cases, the expansion of ophthalmology clinics, the availability of anti-angiogenic drugs, and improved retinal diagnostic capabilities.

The choroidal neovascularization market size is anticipated to undergo significant expansion in the next few years, projected to reach $5.99 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.4%. This expected growth within the forecast period is influenced by an increasing aging population, a rising emphasis on early ophthalmic intervention, the expansion of combination therapy approaches, growing investments in retinal disease research, and the increasing adoption of personalized treatment protocols. Prominent trends for the forecast period include the increasing adoption of anti-VEGF therapies, the rising use of treat-and-extend regimens, a growing demand for early CNV diagnosis, the expansion of advanced retinal imaging techniques, and an enhanced focus on vision preservation therapies.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21142&type=smp

What Drivers Are Influencing The Choroidal Neovascularization Market?

The increasing incidence of age-related macular degeneration (AMD) is anticipated to drive the expansion of the choroidal neovascularization (CNV) market moving forward. Age-related macular degeneration (AMD) is an eye ailment that progressively damages the macula, culminating in central vision impairment, mainly affecting older individuals. The escalating prevalence of age-related macular degeneration (AMD) results from factors such as the aging population, extended life expectancy, alterations in lifestyle, genetic predisposition, and heightened exposure to environmental risks. Choroidal neovascularization (CNV) affects age-related macular degeneration (AMD) patients by facilitating the emergence of wet AMD, where the proliferation of anomalous blood vessels beneath the retina leads to a decline in vision, requiring sophisticated treatments like anti-VEGF therapy to manage choroidal neovascularization (CNV) and slow the advancement of age-related macular degeneration (AMD), ultimately safeguarding central vision in those impacted. For example, in 2025, as per the UHN Foundation, Canada-Based official fundraising arm, age-related macular degeneration (AMD) is identified as the principal cause of substantial, irreversible vision loss in individuals over 50. Currently impacting over 200 million people worldwide, this figure is projected to climb to 288 million by 2040. Consequently, the rising prevalence of age-related macular degeneration is fueling the growth of the choroidal neovascularization market.

Which Segment Areas Are Covered In The Choroidal Neovascularization Market Analysis?

The choroidal neovascularization market covered in this report is segmented –

1) By Treatment Type: Anti-Angiogenic Therapy, Laser Photocoagulation, Photodynamic Therapy, Verteporfin Sodium, Ranibizumab, Bevacizumab, Aflibercept, Pegaptanib Sodium

2) By Indication: Age-Related Macular Degeneration (AMD), Diabetic Macular Edema (DME), Central Serous Chorioretinopathy (CSC), Polypoidal Choroidal Vasculopathy (PCV), Myopic Macular Degeneration (MMD), Other Indications

3) By Route Of Administration: Intravitreal, Subconjunctival, Periocular, Oral

4) By End User: Hospitals, Ophthalmology Clinics, Ambulatory Surgical Centers, Research Centers

Subsegments:

1) By Anti-Angiogenic Therapy (Anti-VEGF Therapy): Ranibizumab, Bevacizumab, Aflibercept, Pegaptanib Sodium

2) By Laser Photocoagulation: Thermal Laser Photocoagulation, MicroPulse Laser Therapy

3) By Photodynamic Therapy (PDT): Standard PDT, Low-Fluence PDT, Half-Dose PDT

4) By Verteporfin Sodium: Intravenous Administration, Combination Therapy With Anti-VEGF

5) By Ranibizumab: Monthly Dosing, As-Needed Dosing, Treat-and-Extend Regimen

6) By Bevacizumab: Off-Label Use, Compounded Intravitreal Injections

7) By Aflibercept: Fixed-Dosing Regimen, Treat-and-Extend Regimen

8) By Pegaptanib Sodium: Monotherapy, Combination Therapy

What Trends Are Advancing Progress In The Choroidal Neovascularization Market?

Key companies operating in the choroidal neovascularization market are concentrating on developing innovative treatments, such as photodynamic therapy, to provide eye care professionals with accurate, efficient treatment options that improve patient outcomes and the delivery of care. Photodynamic therapy (PDT) is a medical procedure that employs a photosensitizing agent activated by light to specifically target and eliminate abnormal or cancerous cells. For instance, in February 2023, Bausch & Lomb, a Canada-based healthcare company, and Modulight, a Finland-based biomedical company, announced the ML6710i photodynamic laser, which received approval from the Food and Drug Administration, a US-based federal agency. This therapy is approved for use alongside Bausch + Lomb’s VISUDYNE therapy, designed to treat choroidal neovascularization resulting from age-related macular degeneration (AMD). This contemporary, mobile ophthalmic laser offers a targeted method for treating abnormal blood vessels in the eye, thereby helping to prevent further disease progression and preserve vision.

Which Global Companies Are Actively Competing In The Choroidal Neovascularization Market?

Major companies operating in the choroidal neovascularization market are Roche Holding AG, Regeneron Pharmaceuticals Incorporated, Bayer Aktiengesellschaft, Novartis AG, Apellis Pharmaceuticals Incorporated, Kodiak Sciences Incorporated, Adverum Biotechnologies Incorporated, Clearside Biomedical Incorporated, Graybug Vision Incorporated, Outlook Therapeutics Incorporated, Oxurion NV, 4D Molecular Therapeutics Incorporated, Opthea Limited, Eyepoint Pharmaceuticals Incorporated, Ocular Therapeutix Incorporated, OcuTerra Therapeutics Incorporated, Ocuphire Pharma Incorporated, Kubota Vision Incorporated, Amgen Incorporated, Coherus BioSciences Incorporated, Formycon AG, Alimera Sciences Incorporated, Neurotech Pharmaceuticals Incorporated, Alkeus Pharmaceuticals Incorporated, Aerie Pharmaceuticals Incorporated, Acucela Incorporated

Read the full choroidal neovascularization market report here:

https://www.thebusinessresearchcompany.com/report/choroidal-neovascularization-global-market-report

Which Regions Are Expected To Experience Rapid Expansion In The Choroidal Neovascularization Market?

North America was the largest region in the choroidal neovascularization market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the choroidal neovascularization market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Choroidal Neovascularization Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21142&type=smp

Browse Through More Reports Similar to the Global Choroidal Neovascularization Market 2026, By The Business Research Company

Cartilage Repair Global Market Report

https://www.thebusinessresearchcompany.com/report/cartilage-repair-global-market-report

Knee Cartilage Repair Global Market Report

https://www.thebusinessresearchcompany.com/report/knee-cartilage-repair-global-market-report

Regenerative Medicine For Cartilage Global Market Report

https://www.thebusinessresearchcompany.com/report/regenerative-medicine-for-cartilage-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795